ONCO on Nasdaq

Onconetix, Inc.

American pharmaceutical preparations company based in Cincinnati.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Seres Therapeutics, Inc., Valion Bio, Inc. or Rallybio, or pick any stock.

  • TickerONCO on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDE
  • Incorporated inDE2
  • Business address201 E. Fifth Street, Suite 1900, Cincinnati, Oh 452022
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

77.6%Gross margin3
-2190.0%Operating margin3
-1721.0%Net margin3
-67.7%Revenue growth, 20253
-89.0%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢$182.5K
  • Selling, general and admin97¢$7.0M
  • Income tax0¢$525

Out of $815.4K in revenue.3 The company lost money this year.

Financial statements

Revenue43$815.4K in 2025+1295% since 2023
0$1.0M$2.0M$3.0M2023: $58.5K$58.5K20232024: $2.5M$2.5M2024+4217%2025: $815.4K$815.4K2025−68%
Gross profit43$632.9K in 2025
-$2.0M-$1.0M0$1.0M$2.0M2023: -$1.1M-$1.1M20232024: $1.1M$1.1M20242025: $632.9K$632.9K2025−40%
Operating income5643-$17.9M in 2025+423% since 2021
-$60.0M-$40.0M-$20.0M02021: -$3.4M-$3.4M20212022: -$13.5M-$13.5M2022+294%2023: -$36.0M-$36.0M2023+167%2024: -$56.5M-$56.5M2024+57%2025: -$17.9M-$17.9M2025−68%
Net income543-$14.0M in 2025+311% since 2021
-$60.0M-$40.0M-$20.0M02021: -$3.4M-$3.4M20212022: -$13.4M-$13.4M2022+293%2023: -$37.4M-$37.4M2023+179%2024: -$58.7M-$58.7M2024+57%2025: -$14.0M-$14.0M2025−76%
Fiscal year202020212022202320242025
Revenue$58.5K4$2.5M3$815.4K3
Cost of revenue$1.2M4$1.5M3$182.5K3
Gross profit-$1.1M4$1.1M3$632.9K3
Research and development$1.3M5$4.1M6$1.9M4$154.4K4
Selling, general and admin$9.4M6$14.8M4$11.2M3$7.0M3
Operating income-$3.4M5-$13.5M6-$36.0M4-$56.5M3-$17.9M3
Interest$671.6K6
Income tax$675.7B5$3.2T5-$12.6K4-$1.0M3$5253
Net income-$3.4M5-$13.4M5-$37.4M4-$58.7M3-$14.0M3
Earnings per share-$1.265-$1.106-$87.454-$1,823.393-$16.563
Earnings per share (diluted)-$1.265-$1.106-$87.454-$1,823.393-$16.563

Compare Onconetix, Inc. with another company

Leadership

Who has led Onconetix, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Neil J. Campbell2023
  2. Ralph Schiess2024–now

Chief financial officer

  1. Bruce Harmon2023
  2. Karina M. Fedasz2024
2025
Board members and other officers (15)

Former names

  • Blue Water Biotech, Inc.Apr 24, 2023 to Dec 18, 20232
  • Blue Water Vaccines Inc.Jul 15, 2019 to Apr 20, 20232

Timeline

  1. Sep 26, 2024New chief executive Ralph Schiess becomes CEO9
  2. Oct 10, 2023New chief executive Neil J. Campbell becomes CEO10

Filings

386 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 125 major events, 69 insider forms, 25 large holders, 2 private raises, 146 other. The latest 20:

  1. Oct 7, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  2. Sep 17, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  3. Sep 14, 2026DEFA14A CURRENT REPORT EDGAR
  4. Sep 14, 20268-K CURRENT REPORT EDGAR
  5. Sep 14, 2026425 EDGAR
  6. Sep 8, 2026424B3 PROSPECTUS EDGAR
  7. Sep 3, 2026EFFECT EDGAR
  8. Sep 3, 2026425 EDGAR
  9. Aug 31, 2026S-1/A AMENDMENT NO. 1 TO FORM S-1 EDGAR
  10. Aug 13, 202610-Q QUARTERLY REPORT EDGAR
  11. Aug 12, 2026S-1 REGISTRATION STATEMENT EDGAR
  12. Aug 6, 2026425 EDGAR
  13. Jul 29, 20268-K CURRENT REPORT EDGAR
  14. Jul 27, 2026SCHEDULE 13G EDGAR
  15. Jul 7, 2026425 EDGAR
  16. Jun 24, 2026425 EDGAR
  17. Jun 17, 2026424B3 PROSPECTUS EDGAR
  18. Jun 16, 2026EFFECT EDGAR
  19. Jun 15, 2026CORRESP EDGAR
  20. Jun 12, 2026UPLOAD EDGAR

The 386 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 25 such filings since October 2021, the latest 10:

  1. Jul 27, 2026SCHEDULE 13G
  2. Jul 16, 2025SCHEDULE 13D/A
  3. Feb 14, 2025SCHEDULE 13D/A
  4. Feb 14, 2025SCHEDULE 13D/A
  5. Feb 13, 2025SCHEDULE 13G/A
  6. Feb 7, 2025SCHEDULE 13G/A
  7. Nov 14, 2024SC 13G
  8. Oct 1, 2024SC 13D
  9. Oct 1, 2024SC 13D
  10. Sep 27, 2024SCHEDULE 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 22, 2025Raised $13 million in a private offering of securities Form D: 11 investors so far Form D
  2. Oct 2, 2024Raised $2 million in a private offering of securities Form D: 5 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
XTX Topco Ltd13,548$15.3K0.0%New
SBI Securities Co., Ltd.252$2850.0%New
Tower Research Capital LLC (TRC)145$1640.0%New
Hollencrest Capital Management100$1130.0%New
Hrt Financial LP51,398$580.0%New
Morgan Stanley21$240.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26